A pilot study of lorazepam-induced amnesia with cis-platinum-containing chemotherapy.
Eighteen patients with advanced epithelial ovarian cancer were given 36 courses of cis-platinum-containing chemotherapy at Cedars-Sinai Medical Center. Patients were given lorazepam (Ativan) prior to chemotherapy. Amnesia for the day of chemotherapy was reported in 29 courses. Lack of recall for the chemotherapy infusion and the subsequent 8 hr or greater was reported in 33 of the 36 courses. In two courses, no amnesia effects were noted. No serious side effects of lorazepam therapy occurred and all patients believed that the amnesic effect was beneficial during chemotherapy. Lorazepam (Ativan) appears to be a safe medication to induce amnesia for cis-platinum chemotherapy and deserves further study to determine its effect on anticipatory vomiting, nausea and vomiting, and patient compliance with continued chemotherapy.
D000328:Adult; D000368:Aged; D002945:Cisplatin / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008140:Lorazepam / Q000627:therapeutic use*; D008568:Memory / Q000187:drug effects*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D014839:Vomiting / Q000139:chemically induced / Q000523:psychology*
D008140:Lorazepam; D002945:Cisplatin